Several different small-molecule ATP-competitive inhibitors to FAK have been developed that exhibit high specificity, can be delivered orally (and in pill form to patients) and exhibit on-target FAK Y397 phosphorylation reduction in tumor and stromal cells (as reviewed by Spallarossa et al., 2022) (Fig. 5). Here, PTK2 is linked to neoplasm.